@article{gristina_waldron_nettifee_munana_2023, title={Comparison of caregivers' assessments of clinical outcome in dogs with idiopathic epilepsy administered levetiracetam, zonisamide, or phenobarbital monotherapy}, volume={261}, ISSN={["1943-569X"]}, DOI={10.2460/javma.22.10.0469}, abstractNote={Abstract

OBJECTIVE
To investigate caregivers’ assessments of outcome in dogs with idiopathic epilepsy (IE) administered levetiracetam (LEV), zonisamide (ZNS), or phenobarbital (PB) monotherapy.


ANIMALS
100 dogs with IE administered LEV (n = 34), ZNS (31), or PB (35) monotherapy between January 1, 2003, and February 6, 2019, and survey responses from their caregivers.


PROCEDURES
Information on duration of therapy, adverse effects (AEs), and outcome was obtained from medical record review and caregiver questionnaire.


RESULTS
A significant improvement in mean quality of life score was reported during monotherapy (7.7; SD, 2.14) compared to before treatment (6.25; SD, 2.63; P < .0001), with no difference identified between monotherapy groups. Compared to ZNS monotherapy, dogs prescribed PB monotherapy had a significantly younger median age at seizure onset (2.6 vs 4.3 years; P = .024). A significant relationship was identified between the occurrence of reported AEs and monotherapy group, with a higher prevalence in the PB group (77% [27/35]) and a lower prevalence in the ZNS group (39% [12/31]; P = .0066). Treatment failure rates for PB, LEV, and ZNS monotherapy were 51%, 35%, and 45%, respectively, with failure attributed most commonly to inadequate seizure control. No significant difference was identified between groups with respect to rate of or time to failure.


CLINICAL RELEVANCE
Most caregivers reported a favorable outcome with administration of LEV, ZNS, or PB monotherapy to dogs with IE. Phenobarbital is associated with the highest prevalence of AEs but no difference in quality of life score. Prospective controlled studies are needed to further compare the efficacy and safety of these monotherapies in dogs with IE.
}, number={7}, journal={JAVMA-JOURNAL OF THE AMERICAN VETERINARY MEDICAL ASSOCIATION}, author={Gristina, Bryanna R. and Waldron, Rennie J. and Nettifee, Julie A. and Munana, Karen R.}, year={2023}, month={Jul}, pages={1020–1027} }
 @article{sims_waldron_marcellin-little_2015, title={Rehabilitation and Physical Therapy for the Neurologic Veterinary Patient}, volume={45}, ISSN={["1878-1306"]}, DOI={10.1016/j.cvsm.2014.09.007}, abstractNote={A comprehensive physiotherapy plan for neurology patients manages pain, prevents secondary complications, and supports the health and function of musculoskeletal tissues during recovery. Neurologically impaired patients range in ability from complete immobility (tetraplegia/paraplegia), partial mobility (tetraparesis/paraparesis), mild ataxia, to pain only. Important considerations for the design of a physiotherapy program include access to the patient, level of staff support, and safety of staff, patient, and client during treatments. A thorough overview of the treatment plan and expected outcome should be discussed with the client at the onset of therapy and should be reviewed frequently, particularly as the patient's status changes.}, number={1}, journal={VETERINARY CLINICS OF NORTH AMERICA-SMALL ANIMAL PRACTICE}, author={Sims, Cory and Waldron, Rennie and Marcellin-Little, Denis J.}, year={2015}, month={Jan}, pages={123-+} }